Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorCHEYSSAC, Elodie
dc.contributor.authorSAVADOGO, Hamidou
dc.contributor.authorLAGOUTTE, Nathan
dc.contributor.authorBAUDOUIN, Veronique
dc.contributor.authorCHARBIT, Marina
dc.contributor.authorNOVO, Robert
dc.contributor.authorSELLIER-LECLERC, Anne-Laure
dc.contributor.authorFILA, Marc
dc.contributor.authorDECRAMER, Stephane
dc.contributor.authorMERIEAU, Elodie
dc.contributor.authorZALOSZYC, Ariane
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorHARAMBAT, Jerome
IDREF: 110567358
dc.contributor.authorROUSSEY, Gwenaelle
dc.date.accessioned2023-02-22T08:09:35Z
dc.date.available2023-02-22T08:09:35Z
dc.date.issued2023-01-10
dc.identifier.issn2296-2360 (Print) 2296-2360 (Electronic) 2296-2360 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/172045
dc.description.abstractEnINTRODUCTION: Primary infection or reactivation of Epstein-Barr Virus (EBV) is a significant cause of morbidity and mortality in pediatric kidney transplantation. Valganciclovir (VGC) treatment is recommended for prophylaxis of cytomegalovirus infection, but its role for the prevention of EBV infection remains controversial. PATIENTS AND METHODS: All pediatric kidney transplant recipients aged <18 years old were considered for inclusion in this retrospective study. EBV negative recipients with an EBV positive donor (a group at risk of primary infection) or EBV positive recipients (a group at risk of reactivation) were included. Severe infection was defined by post-transplant lymphoproliferative disorder (PTLD), symptomatic EBV infection or by asymptomatic EBV infection with a viral load >4.5 log/ml. Outcomes were compared between patients receiving VGC prophylaxis (group P+) and those not receiving VGC prophylaxis (group P-). RESULTS: A total of 79 patients were included, 57 (72%) in the P+ group and 22 (28%) in the P- group; 25 (31%) were at risk of primary infection and 54 (69%) at risk of reactivation. During the first year post-transplant, the occurrence of severe EBV infection was not different between the P+ group (n = 13, 22.8%) and the P- group (n = 5, 22.7%) (p = 0.99). Among patients at risk of primary infection, the rate of severe EBV infection was not different between the two groups (42.1% in P+ vs. 33.3% in P-). A higher frequency of neutropenia was found in the P+ group (66.6%) than in the P- group (33.4%) (p < 0.01). CONCLUSION: Our observational study suggests no effect of VGC for the prevention of EBV infection in pediatric kidney transplant recipients, irrespective of their EBV status. Adverse effects revealed an increased risk of neutropenia.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enProphylaxis
dc.subject.enPediatric kidney transplantation
dc.subject.enValganciclovir
dc.subject.enEpstein–Barr virus
dc.subject.enPTLD
dc.title.enValganciclovir is not associated with decreased EBV infection rate in pediatric kidney transplantation
dc.title.alternativeFront Pediatren_US
dc.typeArticle de revueen_US
dc.identifier.doi10.3389/fped.2022.1085101en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed36704127en_US
bordeaux.journalFrontiers in Pediatricsen_US
bordeaux.volume10en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamLEHA_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-04000007
hal.version1
hal.date.transferred2023-02-22T08:09:41Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Frontiers%20in%20Pediatrics&amp;rft.date=2023-01-10&amp;rft.volume=10&amp;rft.eissn=2296-2360%20(Print)%202296-2360%20(Electronic)%202296-2360%20(Linking)&amp;rft.issn=2296-2360%20(Print)%202296-2360%20(Electronic)%202296-2360%20(Linking)&amp;rft.au=CHEYSSAC,%20Elodie&amp;SAVADOGO,%20Hamidou&amp;LAGOUTTE,%20Nathan&amp;BAUDOUIN,%20Veronique&amp;CHARBIT,%20Marina&amp;rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée